Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections

References

• GirmeniaCNew generation azole antifungals in clinical investigationExpert Opin Investig Drugs200918912791295
   PubMed Web of Science ®Google Scholar
• LivermoreJHopeWEvaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infectionsExpert Opin Drug Metab Toxicol20128675976522530880
   PubMed Web of Science ®Google Scholar
• PasqualottoACDenningDWNew and emerging treatments for fungal infectionsJ Antimicrob Chemother200861Suppl 1i19i3018063600
   PubMed Web of Science ®Google Scholar
• KagoshimaYMoriMSuzukiEDesign, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazoleBioorg Med Chem Lett200313219119612482421
   PubMed Web of Science ®Google Scholar
• WarnPASharpAMosqueraJComparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavusJ Antimicrob Chemother20065861198120717071636
   PubMed Web of Science ®Google Scholar
• DenningDWHopeWWTherapy for fungal diseases: opportunities and prioritiesTrends Microbiol201018519520420207544
   PubMed Web of Science ®Google Scholar
• ChowdharyAKathuriaSRandhawaHSGaurSNKlaassenCHMeisJFIsolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the CYP51A gene in IndiaJ Antimicrob Chemother201267236236622028200
   PubMed Web of Science ®Google Scholar
• HowardSJCerarDAndersonMJFrequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failureEmerg Infect Dis20091571068107619624922
   PubMed Web of Science ®Google Scholar
• GuineaJBouzaEIsavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infectionsFuture Microbiol20083660361519072177
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBHeepMSingle-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteersAntimicrob Agents Chemother200650127928516377698
   PubMed Web of Science ®Google Scholar
• Ostrosky-ZeichnerLInurriaNRodriguezJChenEPaetznickVComparative in vitro activity of isavuconazole (ISA) against medically important yeasts and mouldsPaper presented at: Programs and Abstracts of the 49th Annual; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)2009San Francisco, CA
   Google Scholar
• Schmitt-HoffmannARoosBMaaresJMultiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteersAntimicrob Agents Chemother200650128629316377699
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmannARoosBSauerJEffect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 (WSA) and rifampicinPaper presented at: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology (ISHAM)2006Paris, France
   Google Scholar
• Schmitt-HoffmannARoosBSauerJEffect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of S- and R-warfarinPaper presented at: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology (ISHAM)2006Paris, France
   Google Scholar
• Schmitt-HoffmannARoosBSauerJEffect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of ciclosporinPaper presented at: Abstracts of the Sixteenth Congress of the International Society for Human and Animal Mycology (ISHAM)2006Paris, France
   Google Scholar
• Schmitt-HoffmannARoosBSpickermannJEffect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557Antimicrob Agents Chemother200953114885489019667286
   PubMed Web of Science ®Google Scholar
• Schmitt-HoffmanARoosBSpickermanJNo relevant food effect in man on isavuconazole oral pharmacokinetics preliminary dataPaper presented at: 48th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC)2008Washington, DC
   Google Scholar
• ThompsonGRIIIWiederholdNPIsavuconazole: a comprehensive review of spectrum of activity of a new triazoleMycopathologia2010170529131320524153
   PubMed Web of Science ®Google Scholar
• SeifertHAurbachUStefanikDCornelyOIn vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolatesAntimicrob Agents Chemother20075151818182117307977
   PubMed Web of Science ®Google Scholar
• GuineaJPelaezTRecioSTorres-NarbonaMBouzaEIn vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium speciesAntimicrob Agents Chemother20085241396140018212101
   PubMed Web of Science ®Google Scholar
• Curfs-BrekuerIMMoutonJDebets-OssenkppYJEndtzHPVerweijPEMeisJFIn vitro activity of isavuconazole (BAL4815) compared with seven other antifungal agents against 309 prospectively collected clinical Candida isolates from The NetherlandsPaper presented at: Programs and Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)2007Munich, Germany
   Google Scholar
• Cuenca-EstrellaAGomez-LopezABuitragoMJMelladoERodrigues-TudelaJLBAL4815 a new antifungal agent: determination of quality control limits for susceptibility testing by methods of the european committee on antimicrobial susceptibility testing (EUCAST)Paper presented at: Programs and Abstracts of the 46th Annual International Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting2006San Francisco, CA
   Google Scholar
• HeepMGroverPBrownNPPillarCMJonesMESahmDFEvaluation of isavuconazole e-test compared to broth microdilution antifungal susceptibility testing against quality control strains and clinical Candida isolatesPaper presented at: Programs and Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)2007Munich, Germany
   Google Scholar
• SanglardDIscherFCosteARerrariSComparison between isavuconazole (ISA) and other azoles against characterized clinical isolates and yeast model systemsPaper presented at: Abstracts of the 18th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)2008Barcelona, Spain
   Google Scholar
• MajithiyaJSharpAParmarADenningDWWarnPAEfficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida kruseiJ Antimicrob Chemother200963116116619008255
   PubMed Web of Science ®Google Scholar
• WarnPASharpAParmarAMajithiyaJDenningDWHopeWWPharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effectAntimicrob Agents Chemother20095383453346119451288
   PubMed Web of Science ®Google Scholar
• ViljoenJMithaIHeepMGhannoumMAEfficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs fluconazole in a double-blind, randomized, multicenter trials for the treatment of esophageal candididasis in immunocompromissed adultsPaper presented at: Abstracts of the 45th Conference on Antimicrobial Agents and Chemotherapy (ICAAC)2005Washington, DC
   Google Scholar
• National Institutes of HealthIsavuconazole (BAL8557) in the treatment of candidemia and other invasive Candida infectionsClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://www.clinicaltrials.gov/ct2/show/NCT0413218?term=00413218&rank=1. NLM identifer: NCT0413218Accessed August 16, 2013
   Google Scholar
• National Institutes of HealthEfficacy and pharmacokinetics of an antifungal in patients undergoing chemotherapyClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 Available from: http://www.clinicaltrials.gov/ct2/show/NCT0413439?term=00413439&rank=1. NLM identifier: NCT0413439Accessed August 16, 2013
   Google Scholar
• WarnPASharpADenningDWIn vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus sppJ Antimicrob Chemother200657113513816284102
   PubMed Web of Science ®Google Scholar
• RudramurthySMChakrabartiAGeertsenEMoutonJWMeisJFIn vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility TestingDiagn Microbiol Infect Dis201171437037721937186
   PubMed Web of Science ®Google Scholar
• ShivaprakashMRGeertsenEChakrabartiAMoutonJWMeisJFIn vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugsMycoses2011545e583e58921518026
   PubMed Web of Science ®Google Scholar
• National Institutes of HealthIsavuconazole (BAL8557) for primary treatment of invasive AspergillosisClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://www.clinicaltrials.gov/ct2/show/NCT0412893?term=00412893&rank=1. NLM identfier: NCT0412893Accessed August 16, 2013
   Google Scholar
• Astellas Pharma IncAstellas reports positive topline phase 3 results for antifungal isavuconazolewww.astellas.com/en [website on the Internet]Tokyo, Japan2013 Available from: http://www.astellas.com/en/corporate/news/pdf/130930_2_Eg.pdfAccessed September 30, 2013
   Google Scholar
• National Institutes of HealthIsavuconazole in the treatment of renally impaired aspergillosis and rare fungiClinicalTrials.gov [website on the Internet]Bethesda, MDUS National Library of Medicine2013 Available from: http://www.clinicaltrials.gov/ct2/show/NCT0634049?term=isavuconazole+renal+impairment&rank=2. NLM identifier: NCT0634049Accessed August 16, 2013
   Google Scholar
• Alastruey-IzquierdoACastelliMVCuestaIIn vitro activity of antifungals against ZygomycetesClin Microbiol Infect200915Suppl 5717619754762
   PubMed Web of Science ®Google Scholar
• AlmyroudisNGSuttonDAFothergillAWRinaldiMGKusneSIn vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agentsAntimicrob Agents Chemother20075172587259017452481
   PubMed Web of Science ®Google Scholar
• SunQNNajvarLKBocanegraRLoebenbergDGraybillJRIn vivo activity of posaconazole against Mucor spp. in an immuno-suppressed-mouse modelAntimicrob Agents Chemother20024672310231212069997
   PubMed Web of Science ®Google Scholar
• EnochDAAliyuSHSuleOLewisSJKarasJAPosaconazole for the treatment of mucormycosisInt J Antimicrob Agents201138646547321782392
   PubMed Web of Science ®Google Scholar
• VerweijPEGonzálezGMWiedrholdNPLass-FlörlCIn vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countriesJ Chemother200921327228119567347
   PubMed Web of Science ®Google Scholar
• Illnait-ZaragoziMTMartinezGFCurfs-BreukerIFernandezCMBoekhoutTMeisJFIn Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from CubaAntimicrob Agents Chemother20085241580158218212095
   PubMed Web of Science ®Google Scholar
• ThompsonGRIIIFothergillAWWiederholdNPVallorACWickesBLPattersonTFEvaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformansAntimicrob Agents Chemother20085282959296118559645
   PubMed Web of Science ®Google Scholar
• ThompsonGRIIIWiederholdNPFothergillAWVallorACWickesBLPattersonTFAntifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformansAntimicrob Agents Chemother200953130931118955539
   PubMed Web of Science ®Google Scholar
• ThompsonGRIIIWiederholdNPSuttonDAFothergillAPattersonTFIn vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia speciesJ Antimicrob Chemother2009641798319406849
   PubMed Web of Science ®Google Scholar
• GonzalezGMIn vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungiMed Mycol2009471717619101837
   PubMed Web of Science ®Google Scholar
• KloezenWMeisJFCurfs-BreukerIFahalAHvan de SandeWWIn vitro antifungal activity of isavuconazole against Madurella mycetomatisAntimicrob Agents Chemother201256116054605622964246
   PubMed Web of Science ®Google Scholar
• GuineaJRecioSEscribanoPPelaezTGamaBBouzaEIn vitro antifungal activities of isavuconazole and comparators against rare yeast pathogensAntimicrob Agents Chemother20105494012401520566770
   PubMed Web of Science ®Google Scholar
• BrammerKWFarrowPRFaulknerJKPharmacokinetics and tissue penetration of fluconazole in humansRev Infect Dis199012Suppl 3S318S3262184510
   PubMedGoogle Scholar
• CourtneyRPaiSLaughlinMLimJBatraVPharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adultsAntimicrob Agents Chemother20034792788279512936975
   PubMed Web of Science ®Google Scholar
• LevequeDNivoixYJehlFHerbrechtRClinical pharmacokinetics of voriconazoleInt J Antimicrob Agents200627427428416563707
   PubMed Web of Science ®Google Scholar
• MotonAKrishnaGMaLPharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairmentCurr Med Res Opin20102611719886860
   PubMed Web of Science ®Google Scholar
• PatelKRobertsJALipmanJTettSEDeldotMEKirkpatrickCMPopulation pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targetsAntimicrob Agents Chemother201155125868587321930888
   PubMed Web of Science ®Google Scholar